DOP2019000093A - Formulación de complejo farmacéutica que comprende amlodipina, losartán y clortalidona - Google Patents

Formulación de complejo farmacéutica que comprende amlodipina, losartán y clortalidona

Info

Publication number
DOP2019000093A
DOP2019000093A DO2019000093A DO2019000093A DOP2019000093A DO P2019000093 A DOP2019000093 A DO P2019000093A DO 2019000093 A DO2019000093 A DO 2019000093A DO 2019000093 A DO2019000093 A DO 2019000093A DO P2019000093 A DOP2019000093 A DO P2019000093A
Authority
DO
Dominican Republic
Prior art keywords
losartan
complex formulation
clortalidone
pharmaceutical complex
formulation including
Prior art date
Application number
DO2019000093A
Other languages
English (en)
Spanish (es)
Inventor
Hyun Park Jae
Ii Kim Yong
Soo Woo Jong
Jun Cho Hyuk
Ee Lim Sol
Taek Im Ho
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62076324&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2019000093(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of DOP2019000093A publication Critical patent/DOP2019000093A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DO2019000093A 2016-11-03 2019-04-11 Formulación de complejo farmacéutica que comprende amlodipina, losartán y clortalidona DOP2019000093A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160145518A KR101910902B1 (ko) 2016-11-03 2016-11-03 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제

Publications (1)

Publication Number Publication Date
DOP2019000093A true DOP2019000093A (es) 2019-09-30

Family

ID=62076324

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2019000093A DOP2019000093A (es) 2016-11-03 2019-04-11 Formulación de complejo farmacéutica que comprende amlodipina, losartán y clortalidona

Country Status (12)

Country Link
KR (1) KR101910902B1 (fr)
CO (1) CO2019004798A2 (fr)
CR (1) CR20190264A (fr)
DO (1) DOP2019000093A (fr)
EA (1) EA201991107A1 (fr)
EC (1) ECSP19038749A (fr)
MX (1) MX2019005178A (fr)
NI (1) NI201900046A (fr)
PH (1) PH12019500778A1 (fr)
SG (1) SG11201903145TA (fr)
WO (1) WO2018084627A2 (fr)
ZA (1) ZA201902718B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200143914A (ko) * 2019-06-17 2020-12-28 주식회사유한양행 암로디핀 또는 이의 염 및 클로르탈리돈 또는 이의 염을 포함하는 다층 정제 형태의 약학 조성물
KR20210074428A (ko) 2019-12-11 2021-06-22 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
CN115666564B (zh) 2020-06-09 2024-07-16 韩美药品株式会社 在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂
CR20220664A (es) * 2020-06-09 2023-03-03 Hanmi Pharm Ind Co Ltd Preparación farmacéutica de complejo, para prevenir o tratar enfermedades cardiovasculares, que compone de amlodipina, losartán y clortalidona en comprimido monocapa
CR20230266A (es) * 2020-12-18 2023-07-19 Daewoong Pharmaceutical Co Ltd Nueva formulación para administración oral, que comprende 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina
CN114705785B (zh) * 2022-04-21 2023-11-07 厦门泓益检测有限公司 一种植物油中氯酞酸的检测方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ303145B6 (cs) * 2002-01-16 2012-05-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Zpusob výroby dvojvrstevné farmaceutické tablety obsahující telmisartan a hydrochlorthiazid
EP1648515B1 (fr) * 2003-07-16 2012-11-21 Boehringer Ingelheim International GmbH Combinaisons de chlorthalidone
KR100924236B1 (ko) * 2009-06-23 2009-10-29 충남대학교산학협력단 균일한 입도분포를 가지는 초미세입자의 신규한 제조방법 및 장치
KR20150079373A (ko) * 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
KR101914930B1 (ko) * 2015-03-31 2018-11-05 한미약품 주식회사 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제

Also Published As

Publication number Publication date
KR20180049510A (ko) 2018-05-11
MX2019005178A (es) 2019-08-05
CR20190264A (es) 2019-08-26
WO2018084627A3 (fr) 2018-07-26
ZA201902718B (en) 2020-08-26
NI201900046A (es) 2019-10-11
SG11201903145TA (en) 2019-05-30
CO2019004798A2 (es) 2019-05-21
WO2018084627A2 (fr) 2018-05-11
KR101910902B1 (ko) 2018-10-24
ECSP19038749A (es) 2019-06-30
EA201991107A1 (ru) 2019-09-30
PH12019500778A1 (en) 2019-07-24

Similar Documents

Publication Publication Date Title
ECSP19038749A (es) Formulación de complejo farmacéutica que comprende amlodipina, losartán y clortalidona
CL2017003459A1 (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
CL2018000684A1 (es) Moduladores de la proteína de núcleo de la hepatitis b.
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
BR112018010720A2 (pt) agonistas do receptor de apelina e métodos de uso
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
BR112018003110A2 (pt) nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos
BR112016023422A8 (pt) dispersão seca por spray, composição farmacêutica e seus usos, kit e comprimido
CO2017002472A2 (es) Formulación de acetato de abiraterona
CL2018001298A1 (es) Un proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico
CL2015002897A1 (es) Inhibidores de bace1
CL2017001964A1 (es) Encapsulado de agentes activos de alta potencia.
UY37342A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
CU20180035A7 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
CO2018002428A2 (es) Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol
UY36595A (es) Formulación compleja farmacéutica que comprende amlodipina, losartán y clortalidona
DOP2019000015A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
ECSP19000169A (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant
CU20170134A7 (es) 2-tiopirimidinonas
CO2019004796A2 (es) Preparación de complejo farmacéutica que comprende amlodipina, losartán y rosuvastatina
UY35956A (es) Formulación de atazanavir y cobicistat para el tratamiento del vih
CU20150065A7 (es) Compuestos derivados de bencil 4-((2-(triazol-5-il)acetamido)metil)piperidin-1- carboxilato activos como inhibidores de autotaxina